Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 2512.12113

Prediction of PLX-4720 Sensitivity in Cancer Cell Lines through Multi-Omics Integration and Attention-Based Fusion Modeling

La Ode Aman·Arfan Arfan·Aiyi Asnaw·Purnawan Pontana Putra·Hamsidar Hasan·Dizky Ramadani Putri Papeo
View original source ↗Read source document ↗Export metadata ↓

Abstract

Predicting the sensitivity of cancer cell lines to PLX-4720, a preclinical BRAF inhibitor, requires models capable of capturing the multilayered regulation of oncogenic signaling. Single-omics predictors are often insufficient because drug response is shaped by interactions among genomic alterations, epigenetic regulation, transcriptional activity, protein signaling, metabolic state, and network-level context. In this study we develop an attention-based multi-omics integration framework using genomic, epigenomic, transcriptomic, proteomic, metabolomic, and protein interaction data from the GDSC1 panel. Each modality is encoded into a latent representation using feed-forward neural networks or graph convolutional networks, and fused through an attention mechanism that assigns modality-specific importance weights. A regression model is then used to predict PLX-4720 response. Across single- and multi-omics configurations, the best performance is achieved by integrating genomics and transcriptomics, which yields validation R2 values above 0.92. This reflects the complementary roles of mutational status and downstream transcriptional activation in shaping sensitivity to BRAF inhibition. Epigenomics is the strongest single-omics predictor, while metabolomics and PPI data contribute additional context when combined with other modalities. Integration of three to five omics layers improves stability but does not surpass the accuracy of the best two-modality combinations, likely due to information redundancy and sample-size imbalance. These findings highlight the importance of modality selection rather than maximal data depth. The proposed framework provides an efficient and biologically grounded strategy for drug response prediction and supports the development of precision pharmacogenomics.

Explore related subjects

q-bio.GN

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

La Ode Aman, Arfan Arfan, Aiyi Asnaw, Purnawan Pontana Putra, Hamsidar Hasan, Dizky Ramadani Putri Papeo. 2025-12-13. Prediction of PLX-4720 Sensitivity in Cancer Cell Lines through Multi-Omics Integration and Attention-Based Fusion Modeling. https://arxiv.org/abs/2512.12113

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Revolutionizing Genomics with Reinforcement Learning Techniques

In recent years, Reinforcement Learning (RL) has emerged as a powerful tool for solving a wide range of problems, including decision-making and genomics. The exponential growth of raw genomic data over the past two decades has exceeded the capacity of manual analysis, leading to a growing interest in automatic data analysis and processing. RL algorithms are capable of learning from experience with minimal human supervision, making them well-suited for genomic data analysis and interpretation. One of the key benefits of using RL is the reduced cost associated with collecting labeled training data, which is required for supervised learning. While there have been numerous studies examining the applications of Machine Learning (ML) in genomics, this survey focuses exclusively on the use of RL in various genomics research fields, including gene regulatory networks (GRNs), genome assembly, and sequence alignment. We present a comprehensive technical overview of existing studies on the application of RL in genomics, highlighting the strengths and limitations of these approaches. We then discuss potential research directions that are worthy of future exploration, including the development of more sophisticated reward functions as RL heavily depends on the accuracy of the reward function, the integration of RL with other machine learning techniques, and the application of RL to new and emerging areas in genomics research. Finally, we present our findings and conclude by summarizing the current state of the field and the future outlook for RL in genomics.

q-bio.GN↗
arXiv2026

Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.

q-bio.GN↗
arXiv2026

Large Language Model Agents for Evidence Based Genetic Disease Severity Classification

Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.

q-bio.GN↗